Notice of Results

Syncona Limited

23 May 2024

 

Syncona Limited

Notice of Final Results

23 May 2024

Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, will announce its preliminary results for the period ended 31 March 2024 on Thursday 20 June 2024.  

An in-person presentation for analysts will take place at 9.00am BST, with a webcast available on the Company's website at https://www.synconaltd.com/ or via this link.

[ENDS]

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: [phone]

FTI Consulting

Ben Atwell / Tim Stamper

Tel: [phone]

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses, across development stage and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

 

END